Drug intelligence / Profile preview

Lithoren

Development stage: Unknown
Lead developer: Meditrina Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Lithoren is a specialized dietary supplement, classified as a Food for Special Medical Purposes (FSMP), developed by MEDITRINA for the management and prevention of kidney stones (urolithiasis). Its formulation combines potassium citrate, magnesium citrate, and vitamin B6 (pyridoxine hydrochloride). Lithoren acts as a urine alkalizer, causing a dose-dependent increase in urinary pH and citrate levels. This biochemical shift inhibits the crystallization, aggregation, and formation of calcium oxalate and phosphate complexes, which are the primary constituents of most renal calculi. It is clinically used to prevent stone recurrence and to improve outcomes following lithotripsy procedures.

Brand names: Lithoren

Targets

HydroxyapatiteSPT (Serine palmitoyltransferase)

Beyond the preview

Go deeper on Lithoren.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lithoren.

Explore the full profile